What is the appropriate workup and management for a male patient with low total testosterone?

Low Total Testosterone: Workup and Management

Men with low total testosterone require confirmation with a repeat fasting morning measurement showing levels <300-350 ng/dL combined with specific symptoms of androgen deficiency before initiating testosterone therapy. 1

Initial Diagnostic Workup

Confirm the Diagnosis

• Measure total testosterone on two separate occasions using fasting morning samples (before 10 AM) 1, 2
• Threshold for low testosterone: <300-350 ng/dL (10.4-12 nmol/L) 2, 3
• Use a well-validated assay for measurement 4

Identify Symptoms and Signs

Category A symptoms (more specific):

• Incomplete or delayed sexual development
• Reduced sexual desire (libido) and activity
• Decreased spontaneous erections
• Breast discomfort, gynecomastia
• Loss of body hair, reduced shaving frequency
• Very small or shrinking testes (<5 mL)
• Infertility, low/zero sperm count
• Height loss, low-trauma fracture, low bone mineral density
• Hot flushes, sweats 1

Category B symptoms (less specific):

• Decreased energy, motivation, initiative
• Depressed mood, dysthymia
• Poor concentration and memory
• Sleep disturbance
• Mild normochromic, normocytic anemia
• Reduced muscle bulk and strength
• Increased body fat
• Diminished physical performance 1

Exclude Organic Causes

Rule out permanent hypothalamic, pituitary, or testicular dysfunction (Klinefelter syndrome, orchitis, testicular trauma/radiation, pituitary tumors) 5, 4

Pre-Treatment Evaluation

Absolute Contraindications

• Breast cancer 1
• Prostate cancer 1
• Hematocrit >50% (relative contraindication; >54% is absolute) 1
• Severe untreated obstructive sleep apnea 1

Baseline Testing Required

• Hematocrit 1
• PSA and digital rectal examination in men ≥40 years old 1
  • Do NOT initiate therapy if PSA >4.0 ng/mL 6
  • Do NOT initiate if PSA >3.0 ng/mL in high-risk men (African Americans, first-degree relatives with prostate cancer) 1
  • Do NOT initiate if palpable prostate nodule or induration present 1
• Bone mineral density if osteoporosis or low-trauma fracture present 1

Critical caveat: Men with baseline PSA >0.6 ng/mL require more intensive prostate monitoring 1

Treatment Initiation

First-Line Approach

Lifestyle modification should precede or accompany testosterone therapy in overweight/obese men 4. However, if symptoms are significantly impacting quality of life and testosterone is unequivocally low, therapy can be initiated concurrently.

Testosterone Formulations (Choose Based on Patient Preference)

• Injectable testosterone enanthate or cypionate: 75-100 mg IM weekly OR 150-200 mg every 2 weeks 1
• Transdermal gel (1%): 5-10 g applied daily to non-genital skin 1
• Transdermal patches: One or two 5-mg patches applied nightly to back, thigh, or upper arm 1
• Buccal testosterone: 30 mg every 12 hours 1

Goal: Achieve mid-normal testosterone range (450-600 ng/dL or 400-700 ng/dL for injectables) 1, 3

Monitoring Protocol

Initial Follow-Up (3-6 Months)

• Clinical assessment: Symptom response and adverse effects 1
• Testosterone level: Adjust dose to achieve mid-normal range 1
  • For injectables: measure midway between injections
  • For patches: measure 3-12 hours after application
  • For gels: measure anytime after 1 week of treatment
• Hematocrit: Stop therapy if >54%; evaluate for hypoxia/sleep apnea before reinitiating at reduced dose 1
• PSA and digital rectal examination (in men ≥40 years) 1

Annual Monitoring

• Clinical assessment
• Testosterone level
• Hematocrit
• PSA and digital rectal examination (age-appropriate) 1

Indications for Urological Referral

Obtain urological consultation immediately if: 1

• PSA increase >1.4 ng/mL within any 12-month period
• PSA velocity >0.4 ng/mL/year (using 6-month level as reference, only if >2 years of data)
• Palpable prostatic abnormality on digital rectal examination
• AUA/IPSS symptom score >19

Formulation-Specific Monitoring

• Gels: Counsel about transfer risk; patients must cover application sites and wash skin before skin-to-skin contact 1
• Injectables: Ask about mood/libido fluctuations 1
• Patches: Inspect for skin reactions 1
• Buccal: Examine gums/oral mucosa for irritation 1

Special Populations

Older Men

Do NOT offer testosterone therapy as a general policy to all older men with low testosterone 6, 1. Consider therapy only on an individualized basis when testosterone is consistently low on multiple occasions AND clinically significant symptoms are present, after explicit discussion of uncertain long-term safety 6, 1.

Men with Sexual Dysfunction

Offer testosterone therapy to men with low libido and unequivocally low testosterone 6, 1. For erectile dysfunction, testosterone therapy should be considered after evaluation of underlying causes and consideration of established ED therapies 1.

Key Clinical Pitfalls

1. Never initiate therapy based on a single testosterone measurement 1, 2
2. Do not treat based on symptoms alone without biochemical confirmation 1, 4
3. Approximately 20% of men prescribed testosterone have levels >300 ng/dL—this represents inappropriate prescribing 5
4. Hematocrit elevation is dose-dependent and more pronounced in older men—monitor closely 1
5. Testosterone therapy does not increase cardiovascular or prostate cancer risk based on recent large trials, but long-term safety data remain incomplete 2, 3, 4